Lilly's Jaypirca gains FDA expanded indication for untreated CLL/SLL

The U.S. FDA has granted an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor, for patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).